Luforbec 100/6 pMDI combines the inhaled corticosteroid beclometasone and the long-acting β2 agonist formoterol in an extrafine formulation equivalent to Fostair 100/6 pMDI. The extrafine particle size results in a more potent effect of beclometasone dipropionate than non-extrafine formulations.
Luforbec is licensed for the same indications as Fostair 100/6 pMDI. In adult asthma, Luforbec is indicated for regular treatment where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate. This includes patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β2 agonist, and patients already adequately controlled on both inhaled corticosteroids and long-acting β2 agonists.
Luforbec can be used as regular maintenance asthma treatment with a separate as-needed rapid-acting bronchodilator, and as maintenance and reliever therapy - where it is taken as regular asthma maintenance treatment and as needed in response to asthma symptoms.
In COPD, Luforbec is indicated for symptomatic treatment of patients with severe disease (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
The Luforbec pMDI device is similar to the Fostair pMDI, providing 120 metered doses of 100 microgram beclometasone dipropionate and 6 microgram formoterol dihydrate. It includes a dose indicator and can be used with the AeroChamber Plus® spacer for patients who find it difficult to synchronise aerosol actuation with inhalation.
Adverse reactions commonly seen with beclometasone/formoterol are those typically associated with inhaled corticosteroids (eg, pharyngitis, oral candidiasis, dysphonia and pneumonia [in COPD patients]) and long-acting β2 agonists (eg, headache).